Pablo Jiménez, Medical Oncologist at The Royal Marsden NHS Foundation Trust, shared on X:
“Hexavalent OX-40 agonist (INBRX-106) in 1st L PDL1 >|=20 R/M HNSCC.
Open-label phase 2 HexAgon-HN trial
- Double ORR 48 vs 26%
- High activity in HPV+ (PFS6m)
High amount of tox and treatment discontinuation in a population eligible to just Q6W subcutaneous pembrolizumab.
Phase 2b expansion is ongoing.”
You can also read: Pembrolizumab: What Determines Response to PD-1 Blockade?
